In the majority of trials, high expression of STAT1 leads to improved clinical outcomes, but contradictive data has been shown suggesting that the clinical findings of cancer patients with high expression of STAT1 and/or pSTAT1 are poorer as contrasted with low expression patients [31]. This evidence concerns the gene STAT1 and cancer.